Two Rigel Pharma (RIGL) Lead Product Candidates Entered Trials in Q411
Rigel Pharmaceuticals, Inc. (RIGL: Nasdaq) reports two of its lead product candidates entered clinical trials during the fourth quarter of 2011.
The company is evaluating R548, an oral JAK3 inhibitor, as a potential therapeutic for transplant rejection and other systemic immune disorders. The second candidate, R333, is a topical JAK/SYK inhibitor aimed at treating various phases of discoid lupus (lupus of the skin).
Rigel's product pipeline will be the focus of the company's presentation at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9th at 1:30 pm Pacific Time (webcast details below).
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The company is evaluating R548, an oral JAK3 inhibitor, as a potential therapeutic for transplant rejection and other systemic immune disorders. The second candidate, R333, is a topical JAK/SYK inhibitor aimed at treating various phases of discoid lupus (lupus of the skin).
Rigel's product pipeline will be the focus of the company's presentation at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9th at 1:30 pm Pacific Time (webcast details below).
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
- Mylan (MYL) Unit Launches Generic Viramune Tabs
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
